Zanamivir
- Generic Name
- Zanamivir
- Brand Names
- Relenza, Dectova
- Drug Type
- Small Molecule
- Chemical Formula
- C12H20N4O7
- CAS Number
- 139110-80-8
- Unique Ingredient Identifier
- L6O3XI777I
- Background
A guanido-neuraminic acid that is used to inhibit neuraminidase.
- Indication
For the prevention and treatment of influenza A and B.
- Associated Conditions
- Flu caused by Influenza
- Associated Therapies
- -
A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
- Conditions
- InfluenzaInfluenza, Human
- Interventions
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 3000
- Registration Number
- NCT05648448
- Locations
- 🇧🇷
Universidade Federal de Minas Gerais, Minas Gerais, Brazil
🇱🇦Laos-Oxford-Mahosot Wellcome Trust Research unit, Vientiane, Lao People's Democratic Republic
🇳🇵Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal
Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- University of Missouri-Columbia
- Target Recruit Count
- 14
- Registration Number
- NCT04867707
- Locations
- 🇺🇸
University of Missouri, School of Medicine Clinical Research Center, Columbia, Missouri, United States
Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- George Washington University
- Target Recruit Count
- 74
- Registration Number
- NCT04597437
- Locations
- 🇨🇴
Clinica de la Costa SAS, Barranquilla, Colombia
An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT04494412
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese Adults
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT02377401
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China
- Conditions
- Influenza A Virus InfectionInfluenza B Virus Infection
- Interventions
- Drug: ZanamivirDrug: Placebo
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 298
- Registration Number
- NCT01459081
- Locations
- 🇨🇳
The Third Xiangya Hospital Of Central South University, Changsha, China
🇨🇳The First People's Hospital of Hangzhou, Hangzhou, China
🇨🇳The Affiliated Hospital of Inner Mongolia Medical College, Huhehaote, China
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
- Conditions
- Influenza, Human
- Interventions
- First Posted Date
- 2010-11-01
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 626
- Registration Number
- NCT01231620
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
Relenza® Sentinel Site Monitoring Program in Japan
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1575
- Registration Number
- NCT01199744
Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days
- First Posted Date
- 2009-10-05
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00989404
- Locations
- 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States
A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection
- Conditions
- Upper Respiratory Tract InfectionInfluenza
- Interventions
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2011-04-11
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 4
- Registration Number
- NCT00979667
- Locations
- 🇭🇰
Sai Ying Pun Jockey Club General Outpatient Clinic, Hong Kong, Hong Kong
🇨🇳Shau Kei Wan Jockey Club Clinic, Hong Kong, Hong Kong, China
🇭🇰Fanling Family Medicine Centre, Hong Kong, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.